UPDATE: FDA-Approved Product Further Expands Endo's Branded Pharmaceutical Men's Health Portfolio

Endo International plc (NASDAQ: ENDP) (TSX:ENL), announced today the acquisition of rights to Natesto™ (testosteronenasal gel), the first and only testosterone nasal gel for replacement therapyin adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, awholly-owned subsidiary of Trimel Pharmaceuticals Corporation (TSX: TRL).Natesto™ was approved by the U.S. Food and Drug Administration (FDA) in Mayof 2014.Under the terms of the agreement Trimel will receive an upfront payment of $25million and could receive additional payments upon the achievement of certainregulatory and sales milestones. Additionally, Trimel will be responsible forthe manufacture and supply of Natesto™ and Endo will pay a tiered supplyprice for the product. Endo expects the transaction to close in early 2015."We are pleased to acquire the rights to Natesto™ to further enhance ourbranded pharmaceutical portfolio and look forward to leveraging our commercialexpertise in the areas of men's health and urology to support this highlydifferentiated product," said Rajiv De Silva, President and CEO of Endo."Natesto™ offers a unique intranasal delivery system which will expandoptions for appropriate patients seeking testosterone replacement therapy andwe are focused on getting Natesto™ to market as expeditiously as possible."Under the terms of the agreement, Endo receives sole and exclusive commercialrights to the Natesto™ product in the US and Mexico. In addition, Endo willcollaborate on all regulatory and clinical development activities incoordination with Trimel.